Skip to content

Key Takeaways

  • AI is changing the economics of drug development. Practical applications are already helping companies reduce costs and accelerate research, with potentially greater benefits ahead.
  • China is expanding the global pool of promising science. More competition, but also more innovation—and a growing source of assets for pharmaceutical pipelines.
  • Biotech's fundamentals are improving faster than sentiment. Research spending, new medicines and deal-making are all picking up.

A Stronger Foundation for 2027

In recent months, we’ve spent lot of time with biotech management teams, attending conferences and meeting with companies and clients across the United States, Asia and beyond. Despite continued periods of volatility in biotech equities, what we've heard has reinforced our view that the industry is entering 2027 in a stronger position than it has been in for several years.

The US midterm elections and the latest sell-off in AI-related stocks have added to market uncertainty. But neither has materially changed what we're hearing from biotech companies or the fundamental developments shaping our outlook. Policy, financing conditions and valuations will remain important, but the underlying industry trends give us reason for optimism.

Three developments stand out. Artificial intelligence (AI) is beginning to change the economics of drug discovery and development. China's rapidly advancing biotech industry is expanding the global pool of promising science while raising the competitive bar. And capital is returning to research as new therapies advance and large pharmaceutical companies look to replenish their pipelines.

These are not simply long-term possibilities. We're already seeing evidence of change in how companies allocate research dollars, develop medicines and compete for capital. The implications extend well beyond the next product launch or clinical trial.

For investors, the question is whether share prices adequately reflect an industry whose ability to turn science into medicine is improving. In a number of cases, our analysis suggests they do not.

1 | AI Is Changing the Economics of Drug Development

The AI conversations we had were wide-ranging. Some companies pitched drugs designed entirely by AI; others described how the technology is already changing the day-to-day work of finding and developing medicines.

The everyday applications are already paying off. One drug developer is using AI to work out which laboratory experiments are worth pursuing, allowing its scientists to test fewer candidate molecules before finding the right one. Yet AI could ultimately generate more lab work, not less.  As the technology generates promising ideas quickly, the bottleneck shifts from identifying potential drug candidates to testing them in the real world. More ideas to validate means more experiments and, ultimately, more drug programs moving forward. Several others are using it to help draft the thousands of pages of documentation that regulators require—still reviewed by humans but produced far more quickly.

Exhibit 1: AI Is Already Becoming Part of Biotech's Research and Development Process

Source: Benchling and Statista, November 2025. Biotech AI report 2026. Based on the survey results of 104 biotech and pharma companies based in the United States and Europe. 2026 Biotech AI Report | Benchling.

What it Means for Investors

Bringing a new medicine all the way to patients takes years, and many candidates that enter testing never make it to the finish line. Anything that shortens that journey or improves the odds of success changes the economics of biotech, especially for smaller companies, where a single failed trial can be the difference between survival and not.

The nearer term benefits of AI are now showing up as lower costs and quicker timelines, while the opportunity in AI-designer drugs is no longer a distant prospect. AI-designed molecules have already reached late-stage trials, although none has yet been approved. For the newest platforms—those using AI to identify entirely new disease targets rather than design molecules against known ones—initial human validation could come within two to three years. But the decisive test, whether these medicines work in patients, still lies ahead.

2 | China Is Expanding the Global Pool of Promising Science

If there was one topic that came up in nearly every conversation, it was China.

Chinese biotech companies are producing increasingly sophisticated science, moving drug candidates into human trials faster than many Western peers, and becoming central to early-stage drug development worldwide. In September, the Chinese government rolled out a five-year plan to build on that position.

For the sector as a whole, we see this as more opportunity than threat. Large pharmaceutical companies facing patent expirations have been increasingly willing to license assets originated in China—a cost-effective way to refill their pipelines, and one that validates the quality of the underlying science. More high-quality science, wherever it originates, means more promising medicines in the industry’s pipelines and more opportunities for the companies that execute well.

China also remains an important market for Western laboratory suppliers. Several told us spending there is recovering strongly, ahead of some expectations, though still below its 2021–2022 peak.

Exhibit 2: China Is Becoming a Major Source of Global Biopharma Innovation

Sources: Statista, BCG and Alvarez & Marsal. Biopharma Trends 2026 and Global Biopharmaceutical M&A and VC Insights. January 2026.

What it Means for Investors

Competition is changing what investors can see. Several companies described China as a reason to be more selective about what they disclose, particularly on early-stage research. One executive walked us through several programs the company has chosen not to detail publicly until its intellectual property is more secure or the work is closer to human trials.

A company’s pipeline slide used to be a fair guide to its pipeline. Increasingly, the most promising early-stage work is being held back. For companies with a proven record of discovery, that can mean upside the market has not priced. In our view, it rewards fundamental investors who can look beyond the disclosed pipeline to assess the quality of the science, the strength of the platform and a company’s ability to turn discovery into viable drugs.

3 | Biotech's Fundamentals Are Improving Faster than Sentiment

Budgets are still scrutinized; public financing remains selective and concerns about drug pricing have not disappeared.

Yet several underlying indicators suggest conditions are improving.

Research spending is strengthening. Laboratory suppliers, whose order books give an early read on research activity, are seeing demand pick up—led by drug research and development rather than manufacturing. One large supplier has orders running ahead of sales; another raised its outlook on a stronger backlog. Budgets remain tight, but improving visibility into 2027 could unlock more, and private funding remains available even as public markets stay selective.

The science keeps advancing, and established therapies are reaching more patients. Cell therapies developed for cancer are showing promise in lupus and other autoimmune diseases, while a treatment that could allow some bladder cancer patients to avoid bladder removal is approaching regulatory filing. Meanwhile GLP-1 drugs—originally developed to control blood sugar in type 2 diabetes and now widely used for weight management—are becoming accessible to millions of lower-income Americans through Medicaid.

Mergers and Acquisitions (M&A) are back on the agenda. The dollar value of biopharma M&A activity has already surpassed the full-year 2025 total,1 although the pace slowed in September and October as buyers became more selective ahead of the US midterm elections. With the election now behind us, one source of uncertainty has been resolved, although the policy outlook and financing environment will continue to influence dealmaking. Still the underlying drivers of dealmaking remain intact. Two factors support this. First, facing significant patent expirations, large pharmaceutical companies continue to look to biotech to replenish their pipelines, providing a potential source of capital and support for valuations across the sector. Second, a cohort of mid-sized biotech’s with cash from successful product launches are also seeking new pipeline assets and have broadened the base of potential acquirers.

Exhibit 3: The Need to Replenish Pharmaceutical Pipelines Could Support Renewed Dealmaking

Source: Biopharma Dive, Industry Research. As of 19 October 2026.

What it Means for Investors

Drug pricing worries are real. US government programs are expected to pay less for some medicines, and Germany is debating health spending cuts. But the companies we spoke with described the expected impact as manageable, and investor expectations already appear cautious—many forecasts exclude uncertain overseas revenues altogether.

In our view, that creates a low bar. If the news is merely “less bad” than feared, estimates go up. Add rising research spending, a steady flow of new medicines and renewed deal activity, and you have an industry whose fundamentals are improving faster than the market outlook.

Biotech Enters 2027 With Building Momentum

Smarter tools, tougher competition and returning capital—each of these would be a positive on its own. Together, they describe an industry getting better at the thing it exists to do.

Biotech rarely moves in a straight line, and 2026’s volatility is a reminder of how quickly sentiment can change. But our conversations with companies have left us with a clear view: Real progress is being made, and in a number of cases, we don't think share prices fully reflect it. There will be setbacks, and not every company will get it right. But heading into 2027, we see good reasons to be optimistic—and opportunities for fundamental investors willing to look beyond the market's latest swings.